Exclusive Interview with Dr. Xiaobing Chen: New Strategies for Early Screening and Immunotherapy in Esophageal Cancer

Exclusive Interview with Dr. Xiaobing Chen: New Strategies for Early Screening and Immunotherapy in Esophageal Cancer

2024.10.28
At the 2024 Chinese Anti-Cancer Association (CACA) Integration of Esophageal Cancer Academic Conference, Oncology Frontier invited Dr. Xiaobing Chen, Secondary Professor/Chief Physician at the Department of Internal Medicine at Henan Cancer Hospital and Chair of the CACA Esophageal Tumor Integrated Rehabilitation Committee, to provide an in-depth analysis of early signs of esophageal cancer, screening methods, and innovative strategies for clinical application of immune checkpoint inhibitors.
Dr. Christian Chabannon: The Era of Personalized Immunotherapy from a European Perspective

Dr. Christian Chabannon: The Era of Personalized Immunotherapy from a European Perspective

2024.10.28
Recently, the 11th Sino-French Hematology Academic Conference, organized by the Chinese Medical Doctor Association, was successfully held in Tianjin, China, attracting hundreds of top experts and scholars in the field of hematology from both China and abroad. During the conference, "Hematology Frontier" specially invited Dr. Christian Chabannon from the Paoli-Calmettes Institute in Marseille, France, to discuss the strategies of personalized immunotherapy from a European perspective.
Dr. Frédéric Millot: Future Directions in the Treatment of Chronic Myeloid Leukemia (CML) in Children

Dr. Frédéric Millot: Future Directions in the Treatment of Chronic Myeloid Leukemia (CML) in Children

2024.10.28
Recently, the 11th Sino-French Hematology Academic Conference, organized by the Chinese Medical Doctor Association, was successfully held in Tianjin, attracting hundreds of top experts and scholars in the field of hematology from China and abroad. During the conference, Dr. Frédéric Millot from the University Hospital of Poitiers, France, was invited by "Hematology Frontier" to share the future directions in the treatment of chronic myeloid leukemia (CML) in children.
Dr. Lanfang Li and Dr. Weiyun Zhuang Discuss Mycosis Fungoides and Sézary Syndrome

Dr. Lanfang Li and Dr. Weiyun Zhuang Discuss Mycosis Fungoides and Sézary Syndrome

2024.10.28
The 5th Tianjin International Lymphoma Academic Conference, serving as an academic platform to foster international academic exchange and cooperation, has actively played its role as a bridge, facilitating in-depth exchange and collaboration in the field of international lymphoma. During the conference, "Hematology Frontier" specially invited Dr. Lanfang Li from the Tianjin Medical University Cancer Institute and Hospital and Dr. Weiyun Zhuang from the University of California, San Francisco (UCSF) School of Medicine, to engage in a China-International dialogue, reviewing the latest treatment strategies for mycosis fungoides (MF) and Sézary syndrome (SS).
Dr. Lihua Qiu and Dr. Swaminathan Iyer Discuss the Latest Advances and Optimal Strategies for Peripheral T-Cell Lymphoma Treatment

Dr. Lihua Qiu and Dr. Swaminathan Iyer Discuss the Latest Advances and Optimal Strategies for Peripheral T-Cell Lymphoma Treatment

2024.10.28
The 5th Tianjin International Lymphoma Academic Conference, serving as an academic platform to foster international academic exchange and cooperation, has actively played its role as a bridge, facilitating in-depth exchange and collaboration in the field of international lymphoma. During the conference, "Hematology Frontier" specially invited Dr. Lihua Qiu from Tianjin Medical University Cancer Institute and Hospital and Dr. Swaminathan Iyer from The University of Texas MD Anderson Cancer Center to engage in a China-International dialogue, reviewing the latest therapeutic advances in peripheral T-cell lymphoma (PTCL) and the optimization direction of treatment strategies.
STTT | Breakthrough in Kidney Cancer by Academician Xu Zhang’s Team! Neoadjuvant Regimen of Toripalimab Combined with Axitinib Assists RCC Patients with Tumor Thrombus Downstaging

STTT | Breakthrough in Kidney Cancer by Academician Xu Zhang’s Team! Neoadjuvant Regimen of Toripalimab Combined with Axitinib Assists RCC Patients with Tumor Thrombus Downstaging

2024.10.27
Radical nephrectomy combined with venous tumor thrombus resection is the preferred treatment for renal cell carcinoma (RCC) with inferior vena cava tumor thrombus (IVC-TT) and can significantly improve patient prognosis. Preoperative neoadjuvant therapy aimed at reducing tumor thrombus level and grade is of great importance in reducing perioperative risks. Recently, the NEOTAX study, led by Academician Xu Zhang, Professor Xin Ma, and Professor Liangyou Gu from the Chinese People's Liberation Army General Hospital, was presented at the ESMO Congress (1701P). The study demonstrated that the neoadjuvant regimen of toripalimab combined with axitinib reduced tumor thrombus levels in 96.0% of RCC patients with IVC-TT and achieved thrombus downstaging in 44% of patients, thereby simplifying the surgical process. The study results were published in the Nature sub-journal Signal Transduction and Targeted Therapy (IF: 40.8). The combined treatment showed significant efficacy in reducing IVC-TT and improving surgical feasibility, offering a new direction for improving the prognosis of such patients. Below are the study details.
Dr. Jiuda Zhao Publishes Breakthrough Study in JCO, Demonstrating Electroacupuncture’s Significant Impact on Triple Antiemetic Therapy for Highly Emetogenic Chemotherapy

Dr. Jiuda Zhao Publishes Breakthrough Study in JCO, Demonstrating Electroacupuncture’s Significant Impact on Triple Antiemetic Therapy for Highly Emetogenic Chemotherapy

2024.10.27
Recently, the team led by Dr. Jiuda Zhao at the Breast Disease Diagnosis and Treatment Center of Qinghai University Affiliated Hospital published their latest research findings in the Journal of Clinical Oncology (JCO), with an impact factor of 42.10. This study is the first to combine the current standard triple antiemetic therapy with electroacupuncture (EA) to address chemotherapy-induced nausea and vomiting (CINV) in breast cancer patients. The results demonstrate that adding EA to the standard triple antiemetic regimen significantly enhances CINV treatment outcomes. This study stands as the highest-impact acupuncture-related research publication in the field of oncology in China, showcasing the scientific prowess and innovative capabilities of Chinese scholars on the international stage. Oncology Frontier invited Dr. Jiuda Zhao to discuss this groundbreaking study.